| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/15/2006 | CN1733304A Anticancer medicine composition containing blood vessel inhibitor |
| 02/15/2006 | CN1733303A Anticancer implantation agent containing blood vessel inhibitor |
| 02/15/2006 | CN1733302A Anticancer implantation agent |
| 02/15/2006 | CN1733301A Anticancer implantation agent |
| 02/15/2006 | CN1733300A Anticancer implantation agent |
| 02/15/2006 | CN1732939A Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer |
| 02/15/2006 | CN1732902A Vitamin contained spray |
| 02/15/2006 | CN1241636C Treatment of epidermlyosis bullosa with thymosin Beta-4 |
| 02/15/2006 | CN1241576C Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/15/2006 | CN1241573C Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoismerase I and topoismerase II inhibitors |
| 02/15/2006 | CN1241569C Novel combination of non sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjuncitivitis |
| 02/15/2006 | CN1241567C Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 |
| 02/15/2006 | CN1241480C Pesticidal and antiparasitic compositions |
| 02/14/2006 | US6998423 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 02/14/2006 | US6998417 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents |
| 02/14/2006 | US6998410 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide |
| 02/14/2006 | US6998389 Captopril; hyaluronidases; phospholipases |
| 02/14/2006 | US6998383 Inhibitors of receptor activator of NF-κB and uses thereof |
| 02/14/2006 | US6998254 Use of ROR for receptors for screening substances useful for the treatment of atherosclerosis |
| 02/14/2006 | US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist |
| 02/14/2006 | US6998231 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 02/14/2006 | US6998134 Biologically active implants |
| 02/14/2006 | US6998130 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 02/14/2006 | US6998129 Comprises association between elastase inhibitor compound of the N-acylaminoamide family and at least one antiinflammatory compound; for improving skin ageing and/or photoageing signs by slowing down connective tissue alterations |
| 02/14/2006 | US6998125 Administering a cytotoxic T-lymphocyte and one agent capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors |
| 02/14/2006 | US6998123 interleukins (IL-11); fibronectins; glycoproteins |
| 02/14/2006 | US6998115 Biodegradable and biocompatible and may be used in a variety of drug delivery systems; suited for the delivery of polynucleotides |
| 02/14/2006 | US6998112 Sleep inducing toothpaste made with natural herbs and a natural hormone |
| 02/14/2006 | US6997909 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/14/2006 | US6997865 Cardiac support device with anti-fibrosis lining |
| 02/14/2006 | US6997863 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2338684C Injectable propofol formulations |
| 02/14/2006 | CA2336597C Hepatitis c inhibitor peptides |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2263167C Ether muscarinic antagonists |
| 02/14/2006 | CA2178605C Pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors |
| 02/09/2006 | WO2006015304A2 Amorphous cell delivery vehicle treated with physical/physicochemical stimuli |
| 02/09/2006 | WO2006014653A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | WO2006014270A2 Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
| 02/09/2006 | WO2006014024A1 Therapeutic agent for psychoneurotic disease |
| 02/09/2006 | WO2006013954A1 Composition containing swelling agent comprising swellable water-soluble polysaccharide and food, obesity preventive, and constipation alleviator each containing the composition |
| 02/09/2006 | WO2006013904A1 Medicinal composition containing meltrin antagonist |
| 02/09/2006 | WO2006013427A2 Treatment of ccr2 mediated diseases or disorders |
| 02/09/2006 | WO2006012958A2 Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 02/09/2006 | WO2005110479A3 Treatments for pancreatic cancer |
| 02/09/2006 | WO2005110085A3 Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060031951 Improved modalities for the treatment of degenerative diseases of the retina |
| 02/09/2006 | US20060030622 Compounds and methods for the treatment of urogenital disorders |
| 02/09/2006 | US20060030607 Compounds for the reduction of excessive food intake |
| 02/09/2006 | US20060030598 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 02/09/2006 | US20060030597 Method of inhibiting angiogenesis |
| 02/09/2006 | US20060030594 Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 02/09/2006 | US20060030588 Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| 02/09/2006 | US20060030576 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| 02/09/2006 | US20060030572 Method of improved diuresis in individuals with impaired renal function |
| 02/09/2006 | US20060030548 Methods of using ryanodine antagonists in treating neural injury |
| 02/09/2006 | US20060030542 Protecting a muscarinic acetylcholine receptor in patient, by administering at least one pyrophosphates with active drug; prevent tissue damage, increasing the efficacy of a therapeutic agent |
| 02/09/2006 | US20060030536 Combination therapies for cancer and proliferative angiopathies |
| 02/09/2006 | US20060030019 HDAC9 polypeptides and polynucleotides and uses thereof |
| 02/09/2006 | US20060029990 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 02/09/2006 | US20060029684 Synergistic treatment of DNA viral infections |
| 02/09/2006 | US20060029682 Treatment of wounds and compositions employed |
| 02/09/2006 | US20060029669 Controlled release nateglimide formulation; reducing blood glucose concentration |
| 02/09/2006 | US20060029662 administering N-ethyl-N'-(3-dimethylaminopropyl) urea; N-ethyl-N'-(3-dimethylaminopropyl) urea methiodide to treat arthritis; antiinflammatory agent |
| 02/09/2006 | US20060029621 Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029596 Administering to the tumor an adenovirus vector, overexpresses an adenovirus death protein; promoting the death of neoplastic cells; telomerase resistance; anticancer biodrugs |
| 02/09/2006 | US20060029595 Methods of using human receptor protein 4-1BB |
| 02/09/2006 | US20060029581 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 02/09/2006 | US20060029580 Method for treating a condition with neural progenitor cells derived from whole bone marrow |
| 02/09/2006 | US20060029575 Compositions and methods for producing and using homogenous neuronal cell transplants |
| 02/09/2006 | US20060029570 Therapeutic PEG solution concentrate |
| 02/09/2006 | US20060029547 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 02/09/2006 | US20060026775 Administering N-Phenyl-2({[(1Z)-1-(thien-2-yl)-ethylidene]amino}oxy)acetamide for inducing and/or stimulating the growth of keratinous fibers and/or slowing the loss and/or increasing the density thereof, notably human hair and/or eyelashes |
| 02/09/2006 | CA2576093A1 Pharmaceutical compostion containing meltrin antagonist |
| 02/09/2006 | CA2575986A1 Method of assuming drug sensitivity to cdk4 inhibitor |
| 02/09/2006 | CA2575612A1 Methods of treating ccr2 mediated diseases or disorders |
| 02/09/2006 | CA2574970A1 A method for managing cholesterol with a serum-free and mitogen-free cytokine mixture |
| 02/09/2006 | CA2574176A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | CA2572638A1 Methods and compositions for treating obesity |
| 02/08/2006 | EP1623990A2 Compositions and methods for the treatment of tumours |
| 02/08/2006 | EP1623989A1 Compositions and methods for the diagnosis of tumours |
| 02/08/2006 | EP1623721A1 Effector cell function inhibitor |
| 02/08/2006 | EP1623712A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or analogues |
| 02/08/2006 | EP1622684A2 Compositions and methods relating to novel compounds and targets thereof |
| 02/08/2006 | EP1622650A2 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
| 02/08/2006 | EP1622630A2 Strontium combinations for the prophylaxis/treatment of cartilage and/or bone conditions |
| 02/08/2006 | EP1622629A2 Controlled release composition containing a strontium salt |
| 02/08/2006 | EP1622624A1 Medicinal compositions comprising n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzenesulfonamide and further cytostatics |
| 02/08/2006 | EP1622621A2 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 02/08/2006 | EP1622619A2 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 02/08/2006 | EP1622617A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 02/08/2006 | EP1622616A2 Inhibitors of akt activity |
| 02/08/2006 | EP1622614A2 Use of a topical medicament comprising riluzole |
| 02/08/2006 | EP1622599A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/08/2006 | EP1622586A2 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/08/2006 | EP1622577A2 Prevention of deficits in neurogenesis with anti-inflammatory agents |
| 02/08/2006 | EP1622554A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |